Intellect Neurosciences Inc. (fka ILNS)

[tencoin]

Re - john1045
What do you think about the recent report of Pfizer, J&J and Intellect ?
These bad news shocked the sick persons and the shareholders !
The reports are too conflicting to each other ...
Pfizer, J&J and Intellect VS LINK: http://www.ncbi.nlm.nih.gov/pubmed/22473769

Patients Forty-six patients with mild to moderate Alzheimer disease.

Interventions Patients received either placebo (n = 19) or bapineuzumab (n = 27) in 3 or 4 ascending dose groups.
Main Outcome Measures Changes between end of study and baseline in the exploratory CSF biomarkers Aß1-42, AßX-42, AßX-40; total tau (T-tau); and phosphorylated tau (P-tau).

Results Within the bapineuzumab group, a decrease at end of study compared with baseline was found both for CSF T-tau (–72.3 pg/mL) and P-tau (–9.9 pg/mL). When comparing the treatment and placebo groups, this difference was statistically significant for P-tau (P = .03), while a similar trend for a decrease was found for T-tau (P = .09). No clear-cut differences were observed for CSF Aß.